{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:34:22Z","timestamp":1774265662426,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.4065\/78.11.1340","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:20:27Z","timestamp":1232760027000},"page":"1340-1346","source":"Crossref","is-referenced-by-count":122,"title":["Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome"],"prefix":"10.4065","volume":"78","author":[{"given":"Tait D.","family":"Shanafelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans L.","family":"Madueme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/78.11.1340_bib1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1365-2141.2002.03669.x","article-title":"Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults","volume":"118","author":"Provan","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/78.11.1340_bib2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/78.11.1340_bib3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.10062","article-title":"Autoimmune hemolytic anemia","volume":"69","author":"Gehrs","year":"2002","journal-title":"Am J Hematol"},{"key":"10.4065\/78.11.1340_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00277-002-0461-8","article-title":"Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses","volume":"81","author":"Kumar","year":"2002","journal-title":"Ann Hematol"},{"key":"10.4065\/78.11.1340_bib5","first-page":"791","article-title":"Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia","volume":"7","author":"Sallah","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.4065\/78.11.1340_bib6","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib7","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.11.1340_bib8","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib9","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib10","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/78.11.1340_bib11","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib12","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0775","article-title":"Expanding use of rituximab in immunopathic disorders","volume":"101","author":"Liebman","year":"2003","journal-title":"Blood"},{"issue":"6, suppl 12","key":"10.4065\/78.11.1340_bib13","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh","year":"2000","journal-title":"Semin Oncol"},{"key":"10.4065\/78.11.1340_bib14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"key":"10.4065\/78.11.1340_bib15","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V97.12.3995","article-title":"Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia","volume":"97","author":"Zecca","year":"2001","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69","author":"Giagounidis","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.4065\/78.11.1340_bib17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib18","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2002-02-0392","article-title":"Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura","volume":"99","author":"Stasi","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib19","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","article-title":"Rituximab for the treatment of refractory autoimmune hemolytic anemia in children","volume":"101","author":"Zecca","year":"2003","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib20","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1182\/blood.V92.9.3490","article-title":"Rituxan in the treatment of cold agglutinin disease [letter]","volume":"92","author":"Lee","year":"1998","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1046\/j.1365-2141.2001.02622-3.x","article-title":"Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma [letter]","volume":"112","author":"Bauduer","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/78.11.1340_bib22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/10428190109097770","article-title":"Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk LymphomA"},{"key":"10.4065\/78.11.1340_bib23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood.V99.3.1096a","article-title":"Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody [letter]","volume":"99","author":"Iannitto","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib24","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","article-title":"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia","volume":"16","author":"Gupta","year":"2002","journal-title":"LeukemiA"},{"key":"10.4065\/78.11.1340_bib25","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V100.6.2260","article-title":"Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"100","author":"Hegde","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ajh.10046","article-title":"Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab [letter]","volume":"69","author":"Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"key":"10.4065\/78.11.1340_bib27","first-page":"223","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders","volume":"88","author":"Trape","year":"2003","journal-title":"HaematologicA"},{"key":"10.4065\/78.11.1340_bib28","first-page":"189","article-title":"B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia [published correction appears in Haematologica. 2002; 87:336]","volume":"87","author":"Zaja","year":"2002","journal-title":"HaematologicA"},{"key":"10.4065\/78.11.1340_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s002770000251","article-title":"Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome","volume":"80","author":"Seipelt","year":"2001","journal-title":"Ann Hematol"},{"key":"10.4065\/78.11.1340_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s002770100340","article-title":"Severe Evans's syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody","volume":"80","author":"Abdel-Raheem","year":"2001","journal-title":"Ann Hematol"},{"key":"10.4065\/78.11.1340_bib31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2141.2003.04211.x","article-title":"Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis","volume":"120","author":"Bourgeois","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/78.11.1340_bib32","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1182\/blood.V99.4.1482","article-title":"Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura","volume":"99","author":"Emilia","year":"2002","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2141.2001.02893.x","article-title":"Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy","volume":"114","author":"Kappers-Klunne","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/78.11.1340_bib34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2141.2002.03430.x","article-title":"Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura","volume":"117","author":"Howard","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/78.11.1340_bib35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1365-2141.2001.03039.x","article-title":"The effect of treatment with Campath-1H in patients with autoimmune cytopenias","volume":"114","author":"Willis","year":"2001","journal-title":"Br J Haematol"},{"key":"10.4065\/78.11.1340_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2001-12-0171","article-title":"High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia","volume":"101","author":"Huhn","year":"2003","journal-title":"Blood"},{"key":"10.4065\/78.11.1340_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1703336","article-title":"Resolution of chronic idiopathic thrombocytopenia purpura following syngeneic peripheral blood progenitor transplant","volume":"29","author":"Zaydan","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.11.1340_bib38","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/sj.bmt.1703237","article-title":"Allogeneic stem cell transplantation for Evans syndrome","volume":"28","author":"Oyama","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/78.11.1340_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.thj.6200148","article-title":"Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab [letter]","volume":"3","author":"Cohen","year":"2002","journal-title":"Hematol J"},{"key":"10.4065\/78.11.1340_bib40","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V98.6.1760","article-title":"Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study","volume":"98","author":"Diz-Kucukkaya","year":"2001","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611627122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611627122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:15:29Z","timestamp":1589505329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611627122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S0025619611627122"],"URL":"https:\/\/doi.org\/10.4065\/78.11.1340","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}